Articles Related to IFN
Treatment of Erdheim-Chester Disease with High Dose Pegylated IFN-α: a Case Report and Literature Review
Erdhein-chester disease is a rare non-Langerhans histocytes that can involve multiple systems, with bone involvement as the most common. We reports a 39-year-old female who visited the hospital due to pain in both lower limbs, combined with clinical manifestations, imaging, and laboratory tests, Erdhein-Chester disease was prelimi narily diagnosed. The diagnosis was confirmed by the presence of BRAF V600E mutation and tissue cells on biopsy of the right tibia. We discussed the disease based on literature review, aiming to improve the understanding of clinicians.
Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis
We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
Immunosenescence in Humans: Changes to the Aged T Lymphocyte Population in Response to Persistent Cytomegalovirus Infection
Immunosenescence describes the decrease in immune function with advancing age, a phenomenon that is associated with changes in the B and T lymphocyte populations. CD8+ T cells display the most dramatic phenotypical and functional changes within the T cell compartment whereby the cohorts of effector and memory T cells expand while the total population and diversity of naive T cells both decline.
